Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Oxford BioDynamics ( (GB:OBD) ) has provided an announcement.
Oxford BioDynamics has secured a £1 million interest-free loan from Vulpes Testudo Fund to provide additional working capital as it seeks further funding in early 2025. The loan, considered a related party transaction, will support the company in extending its cash runway, allowing more time to secure additional equity funding, reflecting efforts to stabilize its financial position and continue operations.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision clinical diagnostic tests for significant diseases. The company offers two main products, EpiSwitch PSE and EpiSwitch CiRT, which are based on its proprietary 3D genomic biomarker platform, EpiSwitch. These tests significantly improve the predictive accuracy of diagnostics, particularly in oncology, and are being expanded to other medical fields. The company operates headquarters and laboratories in Oxford, UK, and has operations in Maryland, USA, and Penang, Malaysia.
YTD Price Performance: -96.21%
Average Trading Volume: 4,584,066
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £3.36M
See more data about OBD stock on TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
